APLT Applied Therapeutics

Applied Therapeutics to Participate in Upcoming Investor Conferences

Applied Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the company will participate in the following upcoming investor conferences:

  • Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45 p.m. ET in New York, NY

  • 2024 Cantor Global Healthcare Conference: Presentation on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.

Live webcasts for the events will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at . A replay of the webcasts will be archived on the Company’s website for 90 days following the event.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

To learn more, please visit and follow the company on Twitter @Applied_Tx.

Contacts

Investors:

Julie Seidel/Andrew Vulis

646-970-0543

Media:



EN
04/09/2024

Underlying

APLTApplied Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Applied Therapeutics

 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Provides Regulatory Update on Govorestat for the ...

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia - Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of November 28, 2024 NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) --  Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announc...

September 18, 2024 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics to Participate in Upcoming Investor Conferences

Applied Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the company will participate in the following upcoming investor conferences: Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45 p.m. ET in New York, NY2024 Cantor Global Healthcare Conference: Presentati...

September 4, 2024 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Reports Second Quarter 2024 Financial Results

Applied Therapeutics Reports Second Quarter 2024 Financial Results NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for the treatment of Classic Galactosemia tentatively scheduled for October 9, 2024Company aligned with the Neurology I Division on plans to submit an NDA under Accelerated Approval for govorestat for the treatment of SORD Deficiency; ...

August 7, 2024 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Added to Russell 3000® Index

Applied Therapeutics Added to Russell 3000® Index NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was added to the Russell 3000® Index, effective after the U.S. market closed on June 28, 2024, as part of the 2024 Russell indexes annual reconstitution. “The addition of Applied to the Russell 3000® index underscores the progress we have made as a public...

July 1, 2024 1 EN
 PRESS RELEASE
Free
APLT Applied Therape...

Applied Therapeutics Reports First Quarter 2024 Financial Results

Applied Therapeutics Reports First Quarter 2024 Financial Results Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025Company discussing potential NDA submission under Accelerated Approval for govorestat for treatment of SORD Deficiency with Neurology I Division of FDA NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company devel...

May 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch